NCT01278108View on ClinicalTrials.gov

First-in-Human Single Ascending and Multiple Dose of GLPG0778

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

May 31, 2011

Conditions
Healthy
Interventions
DRUG

GLPG0778

single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)

DRUG

placebo

single dose, oral solution or capsule (matching corresponding study medication)

DRUG

GLPG0778

multiple dose, capsule, 7 days

DRUG

placebo

multiple dose, capsule, 7 days

Trial Locations (1)

2060

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY